AIMS: The transcription factor FoxO3 contributes to anti-hypertrophic signalling in the heart presumably by regulating autophagic-lysosomal and ubiquitin-proteasomal pathways. We wanted to study FoxO3 function in the adult heart in vivo by expressing a constitutively active mutant of FoxO3 in transgenic mice. METHODS AND RESULTS: We generated transgenic mice in which a tetracycline-regulated constitutively active FoxO3 transgene (FoxO3-CA) is controlled by the heart-specific α-myosin heavy chain promoter. Cardiac-specific expression in adult mice resulted in a decrease in heart weight by 25% and a reduction in stroke volume and cardiac output. The decrease in heart size was due to a reduction in the size of individual cardiomyocytes, whereas there was no evidence for increased cell death. FoxO3 activation was accompanied by the initiation of a foetal gene programme with increased expression of β-myosin heavy chain and natriuretic peptides, and by the activation of AKT and mammalian target of rapamycin signalling. As shown by electron microscopy, FoxO3-CA massively stimulated destruction of sarcomeres and autophagy, and induced expression of LC3-II and BNIP3. When FoxO3-CA expression was shut off in affected mice, cardiac atrophy and dysfunction as well as molecular markers were normalized within 1 month. FoxO3-CA expression did not counteract hypertrophy induced by transverse aortic constriction. CONCLUSION: Heart-specific expression of constitutively active FoxO3 leads to reversible heart atrophy. The reversibility of the phenotype suggests a remarkable ability of the adult myocardium to respond to different regulatory cues.
AIMS: The transcription factor FoxO3 contributes to anti-hypertrophic signalling in the heart presumably by regulating autophagic-lysosomal and ubiquitin-proteasomal pathways. We wanted to study FoxO3 function in the adult heart in vivo by expressing a constitutively active mutant of FoxO3 in transgenic mice. METHODS AND RESULTS: We generated transgenic mice in which a tetracycline-regulated constitutively active FoxO3 transgene (FoxO3-CA) is controlled by the heart-specific α-myosin heavy chain promoter. Cardiac-specific expression in adult mice resulted in a decrease in heart weight by 25% and a reduction in stroke volume and cardiac output. The decrease in heart size was due to a reduction in the size of individual cardiomyocytes, whereas there was no evidence for increased cell death. FoxO3 activation was accompanied by the initiation of a foetal gene programme with increased expression of β-myosin heavy chain and natriuretic peptides, and by the activation of AKT and mammalian target of rapamycin signalling. As shown by electron microscopy, FoxO3-CA massively stimulated destruction of sarcomeres and autophagy, and induced expression of LC3-II and BNIP3. When FoxO3-CA expression was shut off in affected mice, cardiac atrophy and dysfunction as well as molecular markers were normalized within 1 month. FoxO3-CA expression did not counteract hypertrophy induced by transverse aortic constriction. CONCLUSION: Heart-specific expression of constitutively active FoxO3 leads to reversible heart atrophy. The reversibility of the phenotype suggests a remarkable ability of the adult myocardium to respond to different regulatory cues.
Authors: Mark R Heckle; David M Flatt; Yao Sun; Salvatore Mancarella; Tony N Marion; Ivan C Gerling; Karl T Weber Journal: Heart Fail Rev Date: 2016-03 Impact factor: 4.214
Authors: Bridget Simonson; Vinita Subramanya; Mun Chun Chan; Aifeng Zhang; Hannabeth Franchino; Filomena Ottaviano; Manoj K Mishra; Ashley C Knight; Danielle Hunt; Ionita Ghiran; Tejvir S Khurana; Maria I Kontaridis; Anthony Rosenzweig; Saumya Das Journal: Sci Signal Date: 2017-02-28 Impact factor: 8.192
Authors: Z Li; J Zhao; I Tikhanovich; S Kuravi; J Helzberg; K Dorko; B Roberts; S Kumer; S A Weinman Journal: Cell Death Differ Date: 2015-10-16 Impact factor: 15.828
Authors: Merry L Lindsey; Rugmani Padmanabhan Iyer; Rogelio Zamilpa; Andriy Yabluchanskiy; Kristine Y DeLeon-Pennell; Michael E Hall; Abdullah Kaplan; Fouad A Zouein; Dustin Bratton; Elizabeth R Flynn; Presley L Cannon; Yuan Tian; Yu-Fang Jin; Richard A Lange; Dorota Tokmina-Roszyk; Gregg B Fields; Lisandra E de Castro Brás Journal: J Am Coll Cardiol Date: 2015-09-22 Impact factor: 24.094